Evidence map›Paper›PMID 34838092›Full record

ArticleInfectious agents and cancer2021

Low frequency of HPV positivity in breast tumors among patients from south-central Poland.

Beata Biesaga, Anna Janecka-Widła, Marta Kołodziej-Rzepa, Anna Mucha-Małecka, Dorota Słonina, Marek Ziobro, Joanna Wysocka, Agnieszka Adamczyk, Kaja Majchrzyk, Joanna Niemiec and 3 more

Open access · goldAbstract read
In one paragraph

Article in Infectious agents and cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. HPV-Associated Breast Cancer: Myth or Fact?Pathogens (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Beata BiesagaCenter for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15, 44-101, Gliwice, Poland. beata.biesaga@io.gliwice.pl.ORCID http://orcid.org/0000-0001-9680-8140
Anna Janecka-WidłaDepartment of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Marta Kołodziej-RzepaDepartment of General, Oncological and Vascular Surgery, 5th Military Clinical Hospital, Cracow, Poland.
Anna Mucha-MałeckaDepartment of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Dorota SłoninaCenter for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15, 44-101, Gliwice, Poland.
Marek ZiobroDepartment of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Joanna WysockaDepartment of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Agnieszka AdamczykDepartment of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Kaja MajchrzykDepartment of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Joanna NiemiecInstitute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.
Aleksandra AmbickaDepartment of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Aleksandra Grela-WojewodaDepartment of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
Agnieszka Harazin-LechowskaDepartment of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Gliwice, Poland.
The Maria Sklodowska-Curie National Research Institute of Oncology · PL1 Military Clinical Hospital with Outpatient Clinic · PLNational Institute of Oncology · HUUniversity of Rzeszów · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSome studies suggest that Human Papilloma Virus (HPV) infection is important factor in carcinogenesis of breast tumors. This study' objective was to analyze HPV prevalence in breast cancers of patients from south-central Poland. MATERIALS AND

methodsThe study was performed based on archival paraffin embebbed and formalin fixed blocks in the group of 383 patients with breast cancer. HPV prevalence and its genotype were assessed, respectively by: nested PCR (with two groups of primers: PGMY09/PGMY11 and GP5+/GP6+), quantitative PCR (qPCR). Tumors were classified as HPV positive in case of at least one positive result in nested PCR and positive results in genotyping procedure. For all HPV positive tissues P16 immunostaining was applied in order to confirm active viral infection.

resultsIn the group of 383 breast cancers, HPV positivity was found in 17 samples (4.4%) in nested PCR. All these samples were subjected to HPV genotyping. This analysis revealed presence of HPV type 16 into two tumors (0.5%). In these two cancers, P16 overexpression was reported.

conclusionIn breast tumors of patients from south-central Poland in Poland, HPV positivity is demonstrated in very low percentage of cases.

Indexed as

Breast cancersHPV infectionSouth-central Poland

Identifiers

PMID34838092
PMCPMC8626918
OpenAlexW3217225956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.